Table 1.
Clinicopathological and molecular characteristics for patients stratified by high and low expression of SCHLAP1.
| Expression of SCHLAP1 (Summarized Per Patient) | |||
|---|---|---|---|
| High (n = 42) | Low (n = 102) | P | |
| Age at surgery | 0.1 | ||
| <60 | 13 (31%) | 24 (24%) | |
| 60–70 | 28 (67%) | 64 (63%) | |
| > 70 | 1 (2%) | 14 (14%) | |
| Preoperative PSA | 0.2 | ||
| <10 ng/ml | 19 (45%) | 46 (45%) | |
| 10 ng/ml–20 ng/ml | 12 (29%) | 41 (40%) | |
| > 20 ng/ml | 11 (26%) | 15 (15%) | |
| Grade group | 0.02* | ||
| 1–2 | 12 (29%) | 47 (46%) | |
| 3 | 10 (24%) | 31 (30%) | |
| 4–5 | 20 (48%) | 24 (24%) | |
| pT stage | 0.006* | ||
| pT2 | 6 (14%) | 42 (41%) | |
| pT3a | 26 (62%) | 46 (45%) | |
| pT3b | 10 (24%) | 13 (13%) | |
| NA | 0 (0 %) | 1 (1%) | |
| Lymph node status | 0.1 | ||
| NX | 22 (52%) | 72 (71%) | |
| N0 | 14 (33%) | 27 (26%) | |
| N1 | 6 (14%) | 3 (3%) | |
| Surgical margin | 0.3 | ||
| Positive | 11 (26%) | 17 (17%) | |
| Negative | 31 (74%) | 85 (83%) | |
| ERG overexpression | < 0.001* | ||
| Yes | 36 (86%) | 33 (32%) | |
| No | 6 (14%) | 69 (68%) | |
| Invasive cribriform growth/IDCP | < 0.001* | ||
| Yes | 34 (81%) | 49 (48%) | |
| No | 8 (19%) | 53 (52%) | |
| Reactive stroma | 0.001* | ||
| Yes | 25 (60%) | 30 (29%) | |
| No | 17 (40%) | 72 (71%) | |
| Biochemical recurrence | < 0.001* | ||
| Yes | 23 (55%) | 21 (21%) | |
| No | 19 (45%) | 81 (79%) | |
| Clinical recurrence | 0.1 | ||
| Yes | 6 (14%) | 7 (7%) | |
| No | 36 (86%) | 95 (93%) | |
| Death (overall survival) | 0.01* | ||
| Yes | 10 (24%) | 8 (8%) | |
| No | 32 (76%) | 94 (92%) | |
Patients were classified as having high expression of SCHLAP1 when at least one malignant sample displayed expression levels above the threshold. A χ2 test of independence or Fisher's exact test was applied to investigate associations between categorical variables. Univariable Cox regression was used to assess association with BCR, clinical recurrence and death (overall survival).
IDCP = intraductal carcinoma of the prostate; PSA = prostate-specific antigen; pT stage = pathological tumor stage.
⁎
indicate statistical significance, P < 0.05.